CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Pembrolizumab (Keytruda) for Mismatch Repair Deficient Endometrial Cancer - Details

Brand Name Keytruda
Generic Name Pembrolizumab
Tumour Type Gynecology
Indication Adult patients with unresectable or metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy.
Review Status Not Filed
Manufacturer Merck Canada Inc.
Submission Type Non-Submission
Clarification CADTH is unable to recommend reimbursement because a submission was not filed by the manufacturer.
Last Updated February 25, 2020